Trilipix Indications/Uses

As an adjunct to diet: In combination with a statin to reduce triglycerides and increase HDL-C in patients with mixed dyslipidemia and CHD or a CHD risk equivalent (other clinical forms of atherosclerotic disease: Peripheral arterial disease, abdominal aortic aneurysm and symptomatic carotid artery disease; diabetes; multiple risk factors that confer a 10-year risk for CHD >20%) who are on optimal statin therapy to achieve their LDL-C.
To reduce trigycerides in patients with severe hypertriglyceridemia.
To reduce elevated LDL-C, total cholesterol, triglycerides and Apo B and increase HDL-C in patients with primary hyperlipidemia or mixed dyslipidemia.
No incremental benefit of Trilipix on cardiovascular morbidity and mortality over and above that demonstrated for statin monotherapy has been established.
Fenofibrate at a dose equivalent to Trilipix 135 mg was not shown to reduce coronary heart disease morbidity and mortality in a large, randomized controlled trial of patients with type 2 diabetes mellitus.